ConductScience.org, home

Paper34745993

Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.

Yu Z and 9 others. Front Oncol, 2021. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study. Papers, record 34745993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34745993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.
PubMed
Journal
Front Oncol
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
1.94
iCite
Revised in PubMed
2022-04-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu ZZaoqin
2Huang RRui
3Zhao LLi
4Wang XXimin
5Shangguan XXiaofang
6Li WWei
7Li MMin
8Yin XXianguo
9Zhang CChengliang
10Liu DDong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127697982Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2016https://conductscience.org/library/papers/27697982PubMed
227221832Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.Asian Pac J Cancer Prev2016https://conductscience.org/library/papers/27221832PubMed
325862137Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.Clin Ther2015https://conductscience.org/library/papers/25862137PubMed
424417770Hypersensitivity to oxaliplatin: clinical features and risk factors.BMC Pharmacol Toxicol2014https://conductscience.org/library/papers/24417770PubMed
515461551A review of oxaliplatin and its clinical use in colorectal cancer.Expert Opin Pharmacother2004https://conductscience.org/library/papers/15461551PubMed
627166187Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.Oncotarget2016https://conductscience.org/library/papers/27166187PubMed
734403109Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.Curr Med Sci2021https://conductscience.org/library/papers/34403109PubMed
820346128Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.J Hematol Oncol2010https://conductscience.org/library/papers/20346128PubMed
912888815Hypersensitivity reactions related to oxaliplatin (OHP).Br J Cancer2003https://conductscience.org/library/papers/12888815PubMed
1028391355Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.Cancer Chemother Pharmacol2017https://conductscience.org/library/papers/28391355PubMed
1127989485Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review.Clin Colorectal Cancer2016https://conductscience.org/library/papers/27989485PubMed
1228687576NCCN Guidelines Insights: Antiemesis, Version 2.2017.J Natl Compr Canc Netw2017https://conductscience.org/library/papers/28687576PubMed
1324769036Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.Gynecol Oncol2014https://conductscience.org/library/papers/24769036PubMed
1428542731Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.Br J Surg2017https://conductscience.org/library/papers/28542731PubMed
1519033714Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.Oncology2009https://conductscience.org/library/papers/19033714PubMed
1622154408Literature review and practical aspects on the management of oxaliplatin-associated toxicity.Clin Colorectal Cancer2012https://conductscience.org/library/papers/22154408PubMed
1712422304Oxaliplatin-related side effects: characteristics and management.Semin Oncol2002https://conductscience.org/library/papers/12422304PubMed
1827461601Oxaliplatin-induced acute thrombocytopenia.J Cancer Res Ther2016https://conductscience.org/library/papers/27461601PubMed
1922534771Oxaliplatin-related thrombocytopenia.Ann Oncol2012https://conductscience.org/library/papers/22534771PubMed
2020497869Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.J Formos Med Assoc2010https://conductscience.org/library/papers/20497869PubMed

See all 47 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42741551Oxaliplatin-induced autoimmune-like hepatitis: A case report highlighting the role of clinical pharmacists.Biomed Rep2026https://conductscience.org/library/papers/42741551PubMed
42396160
Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma.
Front Med (Lausanne)2026https://conductscience.org/library/papers/42396160PubMed
42072487Synergistic Interactions Between Medicinal Plant Bioactive and Standard Chemotherapy in Gastric Cancer: Preclinical Evidence and Translational Pitfalls.Biomedicines2026https://conductscience.org/library/papers/42072487PubMed
41868970Lineage-Specific Disruption of Hematopoiesis by Oxaliplatin: Mechanisms of Erythropoietin Resistance and Immune Suppression.J Hematol Oncol Res2026https://conductscience.org/library/papers/41868970PubMed
41127694Oxaliplatin-Induced Hypersensitivity Reactions Resulting in Respiratory and Cardiac Arrest: A Rare Case.Clin Case Rep2025https://conductscience.org/library/papers/41127694PubMed
40792484Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death.Angew Chem Int Ed Engl2025https://conductscience.org/library/papers/40792484PubMed
40766760Prophylactic administration of lecithinized superoxide dismutase for a murine model of oxaliplatin-induced myelosuppression.Front Pharmacol2025https://conductscience.org/library/papers/40766760PubMed
39286172Huaier relieves oxaliplatin-induced hepatotoxicity through activation of the PI3K/AKT/Nrf2 signaling pathway in C57BL/6 mice.Heliyon2024https://conductscience.org/library/papers/39286172PubMed
38948470Risk of immune system and skin and subcutaneous tissue related adverse events associated with oxaliplatin combined with immune checkpoint inhibitors: a pharmacovigilance study.Front Pharmacol2024https://conductscience.org/library/papers/38948470PubMed
38400666Prediction for oxaliplatin-induced liver injury using patient-derived liver organoids.Cancer Med2024https://conductscience.org/library/papers/38400666PubMed
38161498Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression.J Clin Transl Hepatol2023https://conductscience.org/library/papers/38161498PubMed
36899361Effects of Leea indica leaf extracts and its phytoconstituents on natural killer cell-mediated cytotoxicity in human ovarian cancer.BMC Complement Med Ther2023https://conductscience.org/library/papers/36899361PubMed
36833125The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients.Healthcare (Basel)2023https://conductscience.org/library/papers/36833125PubMed
36552030Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review.Biomedicines2022https://conductscience.org/library/papers/36552030PubMed
36330002Case report: Acute toxic myocardial damage caused by 5-fluorouracil-from enigma to success.Front Cardiovasc Med2022https://conductscience.org/library/papers/36330002PubMed
36245029Attention and Intervention of Oncologists on Oxaliplatin-induced Adverse Reactions in Mainland China: A Cross-sectional Internet-based Survey.Curr Med Sci2022https://conductscience.org/library/papers/36245029PubMed
35919789Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.Pharm Pract (Granada)2022https://conductscience.org/library/papers/35919789PubMed
35833185Case Report: Oxaliplatin-Induced Third-Degree Atrioventricular Block: First Discovery of an Important Side-Effect.Front Cardiovasc Med2022https://conductscience.org/library/papers/35833185PubMed
35739960Antioxidant and Neuroprotective Effect of a Grape Pomace Extract on Oxaliplatin-Induced Peripheral Neuropathy in Rats: Biochemical, Behavioral and Histopathological Evaluation.Antioxidants (Basel)2022https://conductscience.org/library/papers/35739960PubMed
35559366Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.Am J Transl Res2022https://conductscience.org/library/papers/35559366PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34745993

GET https://conductscience.org/api/papers/v1/34745993/references?page=2